[Placental penetration of cefpirome (HR 810): study of fetal concentrations after in vitro infusions of human placenta at term].
Cefpirome (CPO) is a new parenteral cephalosporin with a wide antibacterial spectrum. In order to explore the possibility of using CPO in late pregnancy, we studied its placental transfer in vitro in a model of human placenta infusion. Mother-to-foetus in vitro transfer of CPO is high, similar to that of amoxicillin, with a placental clearance index of 0.20. A pharmacokinetic simulation based upon this result and data from literature suggests that CPO concentrations in foetal blood and amniotic fluid should be appropriate for the treatment of severe materno-foetal infections in late pregnancy. These preliminary results need to be confirmed by in vivo pharmacokinetic and clinical studies before recommending the use of CPO in late pregnancy.
Closse
C
C
Pharmacie de Haut-Lévêque, CHU de Bordeaux, Pessac, France.
Saux
M C
MC
Breilh
D
D
Bouvier d'Yvoire
M
M
Grellet
J
J
Leng
J J
JJ
D000983:Antipyrine / Q000097:blood; D001424:Bacterial Infections / Q000517:prevention & control*; D002511:Cephalosporins / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange / Q000187:drug effects*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D000097572:Cefpirome
D000983:Antipyrine; D002511:Cephalosporins; D000097572:Cefpirome
Pénétration placentaire du cefpirome (HR 810): étude des concentrations foetales après perfusion in vitro de placenta humaine à terme.